FibroGen, Inc. (FGEN)

Market Cap	28.89M
Revenue (ttm)	29.62M
Net Income (ttm)	-47.58M
Shares Out	100.92M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,125
Open	0.2908
Previous Close	0.2776
Day's Range	0.2727 - 0.2920
52-Week Range	0.1800 - 1.7400
Beta	0.88
Analysts	Strong Buy
Price Target	10.00 (+3,336.43%)
Earnings Date	May 5, 2025

About FGEN

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 14, 2014
• Employees: 225
• Stock Exchange: NASDAQ
• Ticker Symbol: FGEN
• Website: https://www.fibrogen.com

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Analyst Forecast

According to one analyst, the rating for FGEN stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(3,336.43% upside)

Analyst Consensus: Strong Buy